No abstract

Oral treatment with ω-3 containing a higher proportion of EPA than DHA increased the effectiveness of topical tacrolimus 0.03% in the treatment of keratoconjunctivitis sicca in dogs.

Background Feline obstructive disease of the lower urinary tract (FLUTD) is a common pathologic condition of cats. It can be related to sterile inflammation, which leads to acute impairment of renal function and the accumulation of electrolytes and acid‐base imbalance. Acute‐phase proteins (APPs) are biomarkers of tissue damage from inflammation that assist in monitoring treatment and prognosis. Objective Monitoring the inflammatory processes of obstructive feline lower urinary tract disease through the determination of plasma fibrinogen concentrations and serum concentrations of the acute‐phase proteins, serum amyloid A (SAA), alpha‐1‐acid glycoprotein (AGP), and albumin. Methodology Twenty‐five male cats were included in this study. They were divided into two experimental groups: a control group (CG) and an obstruction group (OG). There were 8 healthy cats in the CG group and 17 cats with obstructive FLUTD in the OG group. APP measurements were conducted using ELISA kits. Samples were collected for APP analyses, serum biochemical assays, urinalyses, and urine protein: creatinine ratio calculations at diagnosis, before urethral clearance (H0), and 12 (H12), 24 (H24), and 48 (H48) hours after urethral clearance from cats in the OG group. Samples were collected once from cats in the CG group cats. Results At H0, we found positive correlations of SAA, AGP, and fibrinogen with urea and creatinine, and negative correlations of albumin with hematuria, SAA, and potassium. At H48, we found positive correlations between SAA and AGP, AGP and urea, fibrinogen and urea, fibrinogen and creatinine, fibrinogen and AGP, and fibrinogen and SAA. In addition, a negative correlation of albumin with urea and creatinine was observed. Conclusions Serum amyloid A, AGP, fibrinogen, and albumin could be used as biomarkers of inflammatory processes in cats with obstructive FLUTD.

Resveratrol has antioxidant, anti-inflammatory, lipolytic, and antifibrotic properties, which may be useful in supplementation of obese patients and with liver problems. This study evaluated the effects of 6-week resveratrol supplementation on the lipid profile and liver function of female Wistar rats fed a high-fat diet to induce obesity. Sixty-four Wistar rats were divided into 4 groups (n = 16): the control group (C); the control obese group (CO); the resveratrol group (R); and the resveratrol obese group (RO). At the end of the experiment, the animals were anesthetized for blood collection and subsequent euthanasia for collection of liver biopsy. The parameters for body weight, liver weight, retroperitoneal fat weight, serum lipid and liver profiles and histopathological analysis were evaluated. The 6-week resveratrol administration did not induce weight loss nor did it reduce the lipid profile; however, it decreased the liver enzymes aspartate aminotransferase (AST) and alkaline phosphatase (ALP) and reduced the incidence of steatosis (75.0%) in group RO compared with group CO (81.2%). Thus, we concluded that resveratrol supplementation for the short period of six weeks had a beneficial effect on liver function by reducing hepatic steatosis and the liver enzymes AST and ALP in obese female rats. Keywords: liver function; obesity; rats; resveratrol. ResumoO resveratrol possui propriedades antioxidantes, anti-inflamatórias, lipolíticas e antifibróticas que podem ser úteis na suplementação de pacientes obesos e com problemas hepáticos. Este estudo avaliou os efeitos da suplementação de resveratrol durante seis semanas sobre o perfil lipídico e a função hepática de ratas Wistar alimentadas com uma dieta rica em gordura para induzir a obesidade. Sessenta e quatro ratas Wistar foram divididos em 4 grupos (n = 16): grupo controle (C); grupo controle obeso (CO); grupo resveratrol (R); e grupo resveratrol obeso (RO). Ao fim do experimento, os animais foram anestesiados para a coleta de sangue e subsequente eutanásia para coleta de biopsia hepática. Foram avaliados os parâmetros de peso corporal, peso do fígado, peso da gordura retroperitoneal, lipídeos séricos e perfil e análise histopatológica do fígado. A administração de resveratrol por seis semanas não induziu perda de peso nem reduziu o perfil lipídico; no entanto, diminuiu as enzimas hepáticas Cienc. anim. bras., Goiânia, v.17, n.3, p. 402-410 jul./set. 2016Effects of resveratrol on liver function of obese female wistar rats 403 aspartato aminotransferase (AST) e fosfatase alcalina (FA) e reduziu a incidência de esteatose (75,0%) em comparação com o grupo RO grupo CO (81,2%). Assim, conclui-se que a suplementação de resveratrol para o curto período de seis semanas tiveram um efeito benéfico sobre a função do fígado através da redução esteatose hepática e das enzimas do fígado AST e ALP em ratas obesas.